The guideline describes scientific and regulatory considerations for the development, implementation, operation, and lifecycle management of continuous manufacturing (CM). Building on existing ICH Quality guidelines, it provides clarification on CM concepts and describes scientific approaches and regulatory considerations specific to CM of drug substances and drug products for chemical entities and therapeutic proteins. It applies to CM for new products (e.g., new drugs, generic drugs, biosimilars) and the conversion of batch manufacturing to CM for existing products. The principles described in the guideline may also apply to other biological/biotechnological entities.
Source:
EMA: ICH guideline Q13
Write a comment on this news.